{"schema_version":"secwatch.filing_event.v1","accession":"0000920148-25-000093","form_type":"8-K","ticker":"LH","cik":"0000920148","company_name":"LABCORP HOLDINGS INC.","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.606733+00:00","generated_at":"2026-05-17T02:07:14.634521+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Labcorp Q3 adjusted EPS $4.18 vs $3.50; raises FY adjusted EPS midpoint to $16.15-$16.50","bullets":["Revenue $3.56B (+8.6% YoY); diluted EPS $3.12 (vs $2.00); adjusted EPS $4.18 (vs $3.50).","Full-year guidance: revenue growth 7.4%-8.0% (midpoint lowered 40 bps), adjusted EPS $16.15-$16.50 (midpoint +$0.05).","Free cash flow 9M 2025 $715.7M; FY guidance raised to $1.17B-$1.29B.","Acquired oncology assets from BioReference, signed deals with Empire City Labs, Laboratory Alliance, and Crouse Health.","Quarterly dividend $0.72/share payable Dec 11, 2025; repurchased $25M stock in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0000920148-25-000093","json":"https://secwatch.observer/filing/0000920148-25-000093.json","markdown":"https://secwatch.observer/filing/0000920148-25-000093.md","text":"https://secwatch.observer/filing/0000920148-25-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/920148/000092014825000093/0000920148-25-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/920148/000092014825000093/lh-20251028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:07:14.634521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}